tradingkey.logo

BUZZ-ImmunoPrecise Antibodies jumps on AI-powered diabetes treatment

ReutersJan 22, 2025 5:59 PM

** Shares of biotech firm ImmunoPrecise Antibodies IPA.O rise ~42% to 69 cents

** IPA says it has developed a new class of GLP-1 therapies using AI to improve diabetes treatment

** IPA's proprietary tech, called LENSai, uses patterns in biological data to create novel genetic sequences for GLP-1-like constructs

** Co says it is investigating transdermal delivery of these therapies as a non-invasive alternative to injections

** More than 300 mln shares traded, 708x times their 25-day moving avg

** IPA fell ~76% in 2024

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com))

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI